Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 722-730

  Lindborg, K A ^a   Teachey, M K ^a   Jacob, S ^b   Henriksen, E J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Cardio metabolic Institute   (Germany)

Author keywords

CB1 receptor; Insulin resistance; Soleus muscle; SR141716; Zucker rat

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GLUCOSE TRANSPORT SYSTEM; HEART; HYPOXIA; IN VITRO STUDY; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIVER; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SKELETAL MUSCLE; SOLEUS MUSCLE; STATISTICAL SIGNIFICANCE; ZUCKER RAT;

EID: 77958105428     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01227.x     Document Type: Article

References (32)

1. Ferrannini E. Insulin resistance verses insulin deficiency in non-insulindependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-490.
2. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin-and insulin-mediated glucose uptake in humans. Am J Physiol Endocrinol Metab 1988; 255: E769-E774.
3. Nistala R, Stump C. Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 47-52.
4. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 2000; 43: 821-835.
5. Cavuoto P, McAinch AJ, Hatzinikolas G, Janovská A, Game P, Wittert GA. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007; 364: 105-110.
6. Esposito I, Proto MC, Gazzerro P et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008; 74: 1678-1686.
7. Eckardt K, Sell H, Taube A et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009; 52: 664-674.
8. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007; 267: 63-69.
9. Henriksen EJ, Halseth AE. Early alterations in soleus GLUT-4, glucose transport, and glycogen in voluntary running rats. J Appl Physiol 1994; 76: 1862-1867.
10. Hansen PA, Gulve EA, Holloszy JO. Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. J Appl Physiol 1994; 76: 979-985.
11. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacol 2003; 167: 103-111.
12. Cartee GD, Douen AG, Ramlal T, Klip A, Holloszy, JO. Stimulation of glucose transport in skeletal muscle by hypoxia. J Appl Physiol 1991; 70: 1593-1600.
13. Henriksen EJ, Ritter LS. Effects of soleus unweighting on stimulation of insulin-independent glucose transport activity. J Appl Physiol 1993; 74: 1653-1657.
14. Fluckey JD, Ploug T, Galbo H. Mechanisms associated with hypoxia-and contraction-mediated glucose transport in muscle are fibre-dependent. Acta Physiol Scand 1999; 167: 83-87.
15. 2+-dependent mechanism in slow-twitch rat soleus muscle. Am J Physiol Endocrinol Metab 2005; 288: E1062-E1066.
16. ob mice. Int J Obesity 2004; 29: 183-187.
17. Watanabe T, Kubota N, Ohsugi M et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2008; 284: 1803-1812.
18. Tedesco L, Valerio A, Cervino C et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008; 57: 2028-2036.
19. Engeli S, Böhnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
20. Blüher M, Engeli S, Klöting N et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
21. Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
22. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2005; 27: 73-100.
23. Wierzbicki AZ. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006; 60: 1697-1706.
24. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
25. Scheen AJ, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care 2008; 11: 505-511.
26. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-1672.
27. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008; 31 Suppl 2: S229-S240.
28. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. RIOEurope Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008; 29: 1761-1771.
29. Bermúdez-Silva FJ, Serrano A, Diaz-Molina FJ et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531: 282-284.
30. 2+ oscillation in islet β-cells via CB1 receptors. Regul Pept 2008; 145: 49-53.
31. Nogueiras R, Veyrat-Durebex C, Suchanek PM et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57: 2977-2991.
32. De Petrocellis, LD, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Brit J Pharmacol 2004; 141: 765-774.